Inhaled Nitric Oxide for the Adjunctive Therapy of Severe Malaria: a Randomized Controlled Trial
Principal investigator (Uganda):
Robert Opika Opoka, MB ChB., MMed., MPH. Department of Pediatrics & Child Health, Makerere University College of Health Sciences.
Principal investigator (Canada):
- Kevin Kain – MD, FRCPC Professor of Medicine, Canada Research Chair in Molecular Parasitology,
- Director of Global Health – McLaughlin Center for Molecular Medicine, University of Toronto, Director,
- Sandra A. Rotman Laboratories – McLaughlin-Rotman Centre for Global Health, Director, Center for Travel and Tropical Medicine, Toronto General Hospital
- Dr. AbnerTagoola – MBChB, MMED, MPH, Jinja Regional Referral Hospital
- Dr. Sophie Namasopo – MBChB, MMED, Jinja Regional Referral Hospital
- Dr. Chandy C. John – M.D., M.S., Department of Pediatrics, University of Minnesota.
- Dr. W. Conrad Liles – MD, PhD, Department of Medicine, University of Toronto
- Dr. Michael Hawkes – MD, FRCPC, Institute of Medical Sciences, University of Toronto Dr. Christopher Miller, PhD, University of British Columbia
Jinja Regional Referral Hospital, Jinja District.
To determine the efficacy of inhaled nitric oxide for the adjunctive treatment of P. falciparum malaria.
Our specific aim is:
To determine whether supplemental low flow inhaled nitric oxide gas (80 ppm) in addition to Ugandan Standard of Care treatment reduces levels of angiopoeitin-(Ang-2) from baseline in children with moderately severe and severe malaria compared to Standard of Care treatment alone.